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Background: Dyslipidemia and obesity are the most common complex metabolic disorders taking the highest toll
of health resources globally by its increasing incidences. This consequently leads to type 2 diabetes mellitus (T2DM)
and cardiovascular disorders (CVDs) with variable reports about the role of metabolic factors on glycemic control.
The current study is designed to determine the association of dyslipidemia and obesity with glycated hemoglobin
(HbA1c) in T2DM and non-diabetic subjects.
Methods: The present study was carried out in 931 subjects from urban Western India including 430 diabetic and
501 non-diabetic subjects with detailed anthropometric parameters. All subjects were investigated for HbA1c and
lipid parameters like TC, TG, HDL-C, LDL-C and non-HDL-C.
Results: Dyslipidemia, central- and peripheral- obesity were observed (50.27 %; 75 % and 59.83 %) in all the study
subjects respectively. Additionally, hyper-non-HDL-C was detected in 23.49 % and 22.56 % in T2DM and non-diabetic
subjects. Significant linear associations of hyper-TC, hyper-LDL-C and hyper-non-HDL-C were observed with HbA1c in
T2DM and non-diabetic control subjects respectively. Centrally- and peripherally- obese dyslipidemic subjects also
showed a significant association with HbA1c in T2DM and control subjects respectively.
Conclusion: This study demonstrates the high prevalence of dyslipidemia and obesity in all subjects irrespective of
their disease status in a Western Indian population. The dyslipidemic obese subjects had significant linear association
with HbA1c in T2DM subjects.
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Dyslipidemia is associated with more than half of cases
with ischemic heart disease and more than 4 million
deaths per year [1]. In India, a rise in obesity and dyslip-
idemia with increasing urbanization have led to various
lifestyle related disorders like T2DM, CVD and meta-
bolic syndrome [1]. Among dyslipidemic subjects, in-
creased LDL-C, TG and hypo-HDL are established
markers for CAD risk. Additionally, TG-rich lipoproteins
like VLDL and IDL contribute to total atherogenic choles-
terol and are reflected by non-HDL-C which can be used
as a secondary target for lipid lowering agents as proposed
by the National Cholesterol Education Program, Adult* Correspondence: jshethad1@gmail.com
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creativecommons.org/publicdomain/zero/1.0/Treatment Panel III (NCEP-ATP III) [2, 3] and may be
used as the best risk predictor for stroke and cardiovascu-
lar complications [3].
Moreover, more than half a billion people worldwide are
obese [4, 5] and has serious impact on multiple health out-
comes [6]. World Health Organization (WHO) recognizes
obesity and its complications amongst the top 10 global
risk factors leading to ~40 % global deaths [7]. The men-
ace of obesity is attaining an epidemic worldwide due to
changes in life style and food habits. It is defined as a state
of excess adipose tissue mass, and not by the body weight
alone since muscular individuals may possibly have overall
weight gain or high body mass index (BMI) without an in-
crease in adiposity. Thus, those who are not peripherally
obese or overweight might be centrally obese with high
percentage of body fat distributed predominantly in the
abdominal region [8]. In centrally obese individuals,icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Anthropometric and biochemical parameters in T2DM
and control subjects
Parameters
(T = 931 subjects)
T2DM (n = 430) Control (n = 501) p value
Mean ± SD (range) Mean ± SD (range)
Anthropometric indices
Age (Yrs.) 56.57 ± 10.52 48.60 ± 12.95 -
(28.0-86.0) (25.0-86.0)
BMI (Kg/m2) 27.34 ± 5.12 25.83 ± 4.62 0.092
(16.26-51.31) (12.70-47.42)
WC (cm) 96.88 ± 10.28 92.11 ± 10.72 0.542
(65.0-142.0) (64.0-128.0)
Biochemical Parameters
FPG (mg/dl) 140.79 ± 48.31 88.27 ± 12.39 <0.001*
PPPG (mg/dl) 189.53 ± 66.85 ND -
HbA1c (%) 8.18 ± 1.81 5.68 ± 0.51 <0.001*
FI (uIU/ml) 11.02 ± 6.47 11.97 ± 5.44 0.487
HOMA-IR 3.85 ± 2.30 2.67 ± 1.56 <0.001*
TC (mg/dl) 181.56 ± 52.01 181.97 ± 46.18 0.008*
TG (mg/dl) 142.04 ± 73.30 112.03 ± 53.80 <0.001*
HDL-C (mg/dl) 54.24 ± 16.77 56.79 ± 17.33 0.151
LDL-C (mg/dl) 97.94 ± 50.33 102.13 ± 45.14 0.079
Non-HDL-C (mg/dl) 127.32 ± 53.21 125.18 ± 47.10 0.034*
By Independent Student’s t-test, *: Significant, SD: Standard deviation
BMI: Body mass index, WC: Waist circumference, FPG: Fasting plasma glucose,
PPPG: Post prandial plasma glucose, HbA1c: Glycated hemoglobin, FI: Fasting
Insulin, HOMA-IR: Homeostasis Model of Assessment-Insulin Resistance Index,
TC: Total cholesterol, TG: Triglycerides, HDL-C: High-density lipoprotein cholesterol,
LDL-C: Low-density lipoprotein cholesterol, Non-HDL-C: TC-HDL-C
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fatty acids (NEFA), glycerol, hormones, pro-inflammatory
cytokines contributing to insulin resistance (IR) [9, 10].
Asian Indians are found to have higher intra-abdominal
fat, visceral fat and metabolic disturbances as compared to
Caucasians [8, 11] with 3 out of 4 (73 %) urban Indians be-
ing overweight [12]. Based on recently reported prevalence
of obesity in India, it has been shown that every second
urban Indian is obese with the highest risk of weight gain
between 28–38 years [12].
These metabolic dysregulators like dyslipidemia and
obesity along with other lifestyle factors are known to be
associated with T2DM, [2, 13–15] characterized by
hyperglycemia [16]. As per the International Diabetes
Federation (IDF) 2013 estimate, India ranks second
amongst the top 10 countries with 65.1 million diabetic
subjects with an alarming high rate. It is further set to
increase up to 109.0 million with a global estimate of
592 million by the year 2035 [17].
IDF estimates that nearly 175 million individuals are
undiagnosed with diabetes globally [17]. The disease
manifestation takes place much before its clinical ap-
pearance; subjects with T2DM are often asymptomatic
initially as early as 12 years before the diagnosis and
continue to remain asymptomatic throughout the dis-
ease process. Consequently, the age of diagnosis may not
accurately reflect the age of onset of the disease [18].
It will be fruitful to detect early diabetics in India to
curtail the ever increasing incidence of T2DM so that
suitable lifestyle modifications may be suggested to pre-
vent or postpone the onset of T2DM. Our study therefore
attempted to demonstrate the influence of dyslipidemia
and obesity on HbA1c in diabetic and non-diabetic sub-
jects and whether can it be advocated as a combined ‘bio-
marker of lifestyle pattern’. Moreover, the novelty of the
study is an attempt to demonstrate the association of
combined effect of dyslipidemia and obesity on HbA1c in




The current prospective study was carried out on the
Western Indian population (Gujarat and Maharashtra)
that comprised of 931 unrelated participants (430 previ-
ously diagnosed T2DM patients and 501 non-diabetic
control subjects) in the age range of 25 to 89 years. They
were enrolled by consecutive sampling during April,
2012 to October, 2014. All T2DM subjects satisfied the
inclusion criteria of age ≥25 years, duration of diabetes
(≥6 months from the date of diagnosis) and plasma glu-
cose level [Fasting plasma glucose (FPG) >126.0 mg/dl,
post prandial plasma glucose (PPPG) >190.0 mg/dl]. The
inclusion criteria for control subjects were age ≥25 years,plasma glucose level (FPG) <110.0 mg/dl) and HbA1c
level ≤6.5 %. The study was approved by the institutional
ethical committee and ISBEC (Intersystem Biomedica
Ethics Committee). Informed written consent from all
participating subjects was obtained prior to the enrol-
ment. Those with T1DM, other concomitant illness, lac-
tating and pregnant mothers and those who were on
medication of lipid lowering agents (statins, fibrates)
were excluded from the study. Anthropometric parame-
ters such as BMI, waist circumference (WC) and dur-
ation of T2DM were recorded for all the participating
subjects as shown in Table 1. T2DM patients were
treated with biguanides, sulphonylureas, PPARγ activa-
tors, DPP4 inhibitors and α glucosidase inhibitors alone
or in combinations as advised by their physicians.
Anthropometric indices
Weight was measured with light clothes and without
shoes using a digital scale (to the nearest 0.1 kg). Height
was measured without shoes using a stadiometer (to the
nearest 0.1 cm). Waist circumference was measured to
the nearest 0.1 cm. BMI was calculated using the equa-
tion “BMI = weight/height2 (kg/meter2)”. The cut offs
Table 2 Correlation of HbA1c on dyslipidemia and obesity
Parameters
(T = 931 subjects)
T2DM (N = 430) Controls (N = 501)
Association with HbA1c Association with HbA1c
r2 r p r2 r p
Lipid parameters
Hyper TC 0.098 0.312 0.004* 0.030 0.172 0.003*
Normal TC 0.06 0.096 0.085 0.006 0.077 0.125
Hyper TG 0.001 0.036 0.670 0.000 0.010 0.921
Normal TG 0.002 0.043 0.483 0.000 0.019 0.705
Hypo HDL 0.000 −0.009 0.935 0.030 −0.174 0.106
Normal HDL 0.002 −0.050 0.369 0.012 −0.109 0.027*
Hyper LDL 0.101 0.317 0.001* 0.036 0.189 0.031*
Normal LDL 0.004 0.061 0.280 0.023 0.152 0.004*
Hyper non-HDL-C 0.137 0.370 <0.001* 0.050 0.224 0.017*
Normal non-HDL-C 0.001 0.030 0.598 0.031 0.176 0.001*
Obesity
Higher WC 0.000 0.010 0.854 0.001 0.028 0.599
Normal WC 0.002 0.044 0.715 0.012 0.110 0.194
Higher BMI 0.000 0.009 0.887 0.012 0.110 0.071
Normal BMI 0.003 0.099 0.243 0.012 0.112 0.095
By Linear regression and bivariate analysis using Pearson’s correlation
coefficient considering HbA1c as a dependent variable, *: Significant
BMI: Body mass index, WC: Waist circumference, TC: Total cholesterol, TG:
Triglycerides, HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density
lipoprotein cholesterol, non-HDL-C: TC-HDL
Hyper TC: TC ≥ 220 mg/dl, Hyper TG: TG≥ 150 mg/dl respectively, Hypo-HDL:
HDL-C ≤ 40 mg/dl, Hyper-LDL: LDL-C ≥ 130 mg/dl, Hyper-Non-HDL: Non-HDL-C ≥
160 mg/dl, Higher WC: Male WC> 90 cm and Female WC > 80 cm, Higher
BMI: BMI > 25 kg/m2
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were based on the Executive Summary of the Third Report
of the NCEP, ATP III and the IDF guidelines for South-
Asian population [2, 17]. Obesity as a whole was defined
as BMI >25 kg/m2; and central obesity was defined as WC
>90 cm for males and WC >80 cm for females.
Sample collection and handling
Blood samples were collected in fluoride, EDTA and
serum vaccutainers between 8:00 to 11:00 am after 12 h
of fasting for biochemical assays such as FPG, HbA1c,
fasting insulin (FI), insulin resistance (HOMA-IR), and
lipid profile estimation. Blood was collected again after
2 h of consuming non-standardized meal for PPPG esti-
mation for T2DM subjects. Serum was separated within
30–45 min, aliquoted and stored at −20 °C till analysis.
Biochemical investigations
FPG, PPPG and lipid profile including total cholesterol
(TC), triglyceride (TG), and high-density lipoprotein
cholesterol (HDL-C) were measured by colorimetric
method with respective calibrator and biological stan-
dards. All biochemical investigations were carried out by
commercially available kits using an auto-analyzer sys-
tem (BTS 330, Biosystem, Spain). HbA1c was analyzed
by affinity assay using the Nyco Card reader-II (Axis-
Shield, Norway). FI levels were measured by Immuno
Radiometric Assay (IRMA) with a commercial kit
(Immunotech, France). Low-density lipoprotein choles-
terol (LDL-C) and non-HDL-C were calculated by a
standard formula [LDL = TC - HDL-C - (TG/5)] and
[non-HDL-C = TC - HDL-C] [20]. Insulin resistance was
calculated by the Homeostasis Model of Assessment-
Insulin Resistance Index (HOMA-IR) with a model for-
mula [HOMA-IR = (FI × FPG)/405] [21].
The intra assay coefficients of variations for lipid param-
eters were; TC: 1.39 %, TG: 0.50 % and HDL-C: 1.67 %
whereas the inter assay coefficients of variations for afore-
said lipids were; 2.65 %, 1.65 % and 4.69 % respectively.
The cut offs for dyslipidemia used in this study were
based on the IDF guidelines for South-Asian population.
The hypercholesterolemia (hyper-TC) and hypertriglyc-
eridemia (hyper-TG) were considered with TC ≥ 220 mg/dl
and TG ≥ 150 mg/dl respectively; whereas, those with
HDL-C ≤ 40 mg/dl, LDL-C ≥ 130 mg/dl and non-HDL-C ≥
160 mg/dl were considered hypo-HDL-cholesterolemia
(hypo-HDL-C), hyper-LDL-cholesterolemia (hyper-LDL-C)
and hyper-non-HDL-cholesterolemia (hyper-non-HDL-C)
respectively. TC < 220 mg/dl, TG < 150 mg/dl, HDL-C >
40 mg/dl LDL-C < 130 mg/dl and non-HDL-C < 160 mg/dl
were regarded as normal in accordance with IDF and
NCEP guidelines [2, 17]. Dyslipidemia is defined by pres-
ence of one or more abnormal serum lipid biomarker
concentration.Statistical analysis
The sample size yielded a margin of error of 3.3 % in the
study and a confidence limit of 95 % with an on-line cal-
culator [22]. False positive error rate/Type I error was
0.05. The value of HbA1c was given as a percentage of
total hemoglobin; and values of all other lipid parame-
ters were given in mg/dl. All values were expressed as
mean ± standard deviation. Linear regression, bivariate
correlation analysis (using Pearson’s correlation coeffi-
cient) and student’s t-test analysis were carried out with
IBM-SPSS v15.0. p values (two tailed) ≤0.05 were consid-
ered to be statistically significant.Results
Assessment of Anthropometric indices and Biochemical
parameters
Total 931 subjects were included in the study, 430 were
T2DM (diagnosed for >6 months) and 501 were non-
diabetic control subjects. Baseline characteristics of the
participants are summarized in Table 1. The average
duration of diabetes in T2DM subjects at inclusion was
8.39 ± 7.53 years (6 months to 40 years). Significantly
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as compared to non-diabetic control subjects (FPG: p <
0.001 and HbA1c: p <0.001) respectively. Additionally,
higher mean HOMA-IR, TC, TG and non-HDL-C were
also observed in T2DM than in non-diabetic control
subjects (HOMA-IR: p <0.001, TC: p = 0.008, TG: p <
0.001and non-HDL-C: p = 0.034) respectively.Prevalence of dyslipidemia and obesity
Dyslipidemia was seen in 50.27 % of the study population
with highest in T2DM amongst both the groups followed by
control subjects (53.72 % and 47.31 % respectively). Hyper-
TC was observed in 19.76 % (85) and 20.56 % (103) of
T2DM and control subjects respectively. Hyper-TG was
higher in T2DM compared to control subjects [33.26 %
(143) 19.56 % (98)], whereas hypo-HDL-C was 18.61 % (80)
in T2DM and 17.54 % (88) in non-diabetic subjects.
Furthermore, prevalence of hyper-LDL-C and hyper-non-
HDL-C were almost at par in both the groups 23.02 % (99);
vs. 25.95 % and 23.49 % (101) vs. 22.56 % (113) in T2DM
compared to control subjects respectively (Data not shown).
The prevalence of central obesity was found to be higher
(75 %) compared to peripheral obesity (59.83 %) in overall
study population. Higher central obesity was seen in
T2DM as compared to non-diabetic control subjects
[82.56 % (355) vs. 70.26 % (352)] respectively. Similarly, in-
cidence of peripheral obesity was also higher in T2DM than
non-diabetic control subjects [66.27 % (283) vs. 54.29 %
(272)] respectively (Data not shown).Fig. 1 Association of central obesity with HbA1c in dyslipidemic T2DM subAssociation of dyslipidemia, central obesity and
peripheral obesity with HbA1c levels
A significant linear association of hyper-TC, hyper-LDL-C
and hyper-non-HDL-C with HbA1c was observed in
T2DM and control subjects. Though, significant correl-
ation between hyper-TG and hypo-HDL-C to HbA1c was
not observed in subjects of the both groups (Table 2).
Additionally, we also observed an association between
normal HDL-C, LDL-C and non-HDL-C with HbA1c in
control subjects. Though, higher WC or higher BMI per
se had no independent association with HbA1c levels in
any of the groups as shown in Table 2.
Nonetheless, significant linear association was ob-
served in T2DM subjects with central- and peripheral-
obesity along with dyslipidemia, while such correlation
was not seen in non-diabetic subjects (Figs. 1 and 2).
Discussion
The present population-based study was carried out on
subjects from urban Western India with a mixed ethni-
city. The major contributing factor for the higher risk of
developing diabetes is likely to be due to increased
prevalence of central- and peripheral- obesity in all the
study subjects which is almost similar to the previous
observation of ~30-65 % Indian urban being overweight
or obese [23]. Obesity is known to be associated with in-
creased amount of adipose tissue or its disproportionate
distribution between central- and peripheral- body re-
gions which is also related to the development of insulin
resistance, dyslipidemia and CAD that increases thejects
Fig. 2 Association of peripheral obesity with HbA1c in dyslipidemic T2DM subjects
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the storage of lipids in the adipose tissue, adipocytokines
like adiponectin, leptin, TNF, IL-6, resistin play an im-
portant role in tissue physiology and have been shown
to be linked to obesity, insulin resistance and β-cell dys-
function [24]. McTernan et al. in their animal study
showed an increased resistin expression in adipose cells
obtained from abdominal and omental region possibly
contributing to insulin resistance, glucose intolerance
and development of T2DM [25]. This could explain why
obese T2DM subjects with dyslipidemia had poor
hemoglobin glycation as compared to non-obese T2DM
subjects in our study. The present study showed a higher
number of T2DM subjects with central obesity as com-
pared to peripheral obesity, which could be due to
higher rates of lipolysis in visceral fat than subcutane-
ous fat by catecholamines [26]. This may in turn result
into an increased FFA delivery to the liver, consequently
stimulates hepatic glucose production by fatty acids (FA)
causing interference in hepatic insulin removal, and may
further accentuate insulin resistance [26].
Additionally, our subjects with hyper-TC, hyper-LDL-
C and hyper-non-HDL-C alone or combined with obes-
ity in T2DM group have shown poorly controlled
HbA1c as compared to those with normal level of these
parameters. Several reports have shown significant influ-
ence of lipid concentration on hemoglobin glycation and
increased CVD risk possibly due to increased insulin
resistance [27–29]. Nonetheless, these studies hadstratified subjects based on their glycation control and
observed their overall mean of lipid parameters,
whereas in our study we had stratified subjects based
on their dyslipidemia and obesity followed by observation
of glycation pattern. Hyperglycemia promotes increase in
LDL glycation and affinity towards LDL-receptors on
macrophages; stimulate foam cell formation, endothelial
cell toxicity and smooth muscle proliferation responsible
for coronary artery and macrovascular complications [1].
We observed a significant association of non-HDL-C
with HbA1c in our study which is in accordance with a
recent study in Nepalese’ T2DM subjects [27]. Recent
studies have also shown the utility of non-HDL-C as a
significant biomarker for cardiovascular risk assess-
ment and as a secondary target to monitor the effect of
lipid lowering agents [3, 20]. It can be inferred that
subjects with hyper-non-HDL-C are at an increased
risk of CVD.
Our study could not demonstrate significant associ-
ation of hyper-TG levels in T2DM subjects as compared
to non-diabetic control subjects, contrary to the studies
by Ikhas et al., and Schulze et al., which could be due to
poor glycemic control that mask the effects of TG in
higher glycation group [29, 30].
The Lipid Research clinics Coronary Primary Preven-
tion Trial established that each 1 % fall in TC levels re-
sults into 2 % reduction in CAD risk [31]. A study
carried out in Helsinki determined that with 11 % fall in
LDL-C levels, there is 34 % reduced risk of CAD [31].
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19.77 % of T2DM and 20.56 % of non-diabetic controls.
Moreover an increased dyslipidemia is likely to in-
crease HbA1c and vice versa as the correlation between
these parameters are directly proportional and goes
hand-in-hand [27, 32]. Reduction in HbA1c in T2DM is
associated with improved insulin sensitivity and better
lipid parameters.
There are several mechanisms to elicit the effects of
increased physical activity to improve dyslipidemia as it
increases glucose removal and decreases muscle and
hepatic IR through a number of mechanisms that would
not necessarily be associated with changes in body
weight [33]. This is in accordance with our results where
we could not find correlation of HbA1c with BMI
(which is an indicator of overall weight gain). However,
increased physical activity and lifestyle modification
seems to be associated with decreased HbA1c and better
glycemic and lipid control. Thus, targeting to lower the
dyslipidemia and obesity is likely to reduce HbA1c not
only in diabetic subjects but it will have an equal effect
in non-diabetic subjects.Conclusion
Dyslipidemia and obesity are significantly associated
with poorly controlled hemoglobin glycation in T2DM
and non-diabetic subjects. Additionally, higher preva-
lence of non-HDL-C in the study subjects suggesting its
possible role as a biomarker for CVD.Abbreviations
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